EMERYVILLE, Calif.,
Oct. 21, 2021 /PRNewswire/
-- Dynavax Technologies Corporation (Nasdaq:
DVAX), a biopharmaceutical company focused on developing
and commercializing novel vaccines, today announced the
appointment of Scott Myers to its
Board of Directors. Mr. Myers was also elected Board Chairman,
succeeding Dr. Andrew Hack who has
served as interim Chairman of the Board since May 2020. Dr.
Hack will continue to serve on the Board of Directors.
"I am excited to have Scott join the Board of Directors as he
brings tremendous depth and breadth of highly relevant experience
as we continue to accelerate the growth of Dynavax," commented
Andrew Hack, Dynavax Board member
and Managing Director, Bain Capital Life Sciences. "On behalf of
the entire Board, we look forward to working with Scott and the
management team to continue to build a leading vaccine company on
the foundation of significant experience and expertise in vaccine
development and commercialization."
"We are pleased to welcome Scott to our Board of Directors.
Scott brings nearly three decades of global pharmaceutical and
medical technology experience. I look forward to his strategic
guidance as Dynavax continues to build a leading vaccine company on
the foundation of our two highly valuable assets, HEPLISAV-B, our
adult hepatitis B vaccine, and CpG 1018, our vaccine adjuvant
platform," commented Ryan Spencer,
Chief Executive Officer of Dynavax. "I would also like to thank
Andrew for his service as interim Chair and the invaluable advice
and guidance he has and will continue to provide as a member of
this Board."
"I am thrilled to join Dynavax's Board of Directors at this
exciting time in the company's growth," commented Scott Myers. "The strength of the Company's
commercial execution for HEPLISAV-B and the growing set of data
supporting CpG 1018's value as a platform for developing new and
improved vaccines, reinforce the long-term opportunity that Dynavax
represents."
Mr. Myers has worked in the global pharmaceutical and medical
technology industries for nearly three decades. Most recently
he was the Chief Executive Officer and served on the board of
directors of AMAG Pharmaceuticals, Inc., where he led its
turnaround and strategic sale to Covis Pharma, S.à.r.l., a
pharmaceutical company, in November
2020. Mr. Myers has served as Chairman of the board of
directors of Rainier Therapeutics, Inc., an oncology biotechnology
company focused on late-stage bladder cancer, from June 2018 to January
2020, and served as its Chief Executive Officer from
September 2018 to January 2020. Prior to Rainier, Mr. Myers served
as Chief Executive Officer, President and Director for Cascadian
Therapeutics, Inc., an oncology company, from April 2016 through its acquisition by Seattle
Genetics in March 2018. Mr. Myers is
an independent director on the board of directors of Selecta
Biosciences, Trillium Therapeutics, Inc. and Harpoon Therapeutics,
Inc. Mr. Myers holds a B.A. in Biology from Northwestern University and an M.B.A. from the
Graduate School of Business (Booth) at the University of Chicago.
About Dynavax
Dynavax is a commercial stage
biopharmaceutical company developing and commercializing novel
vaccines. The Company's first commercial product, HEPLISAV-B®
[Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the
U.S. and the European Union for prevention of infection caused by
all known subtypes of hepatitis B virus in adults age 18 years and
older. Dynavax is also advancing CpG 1018 adjuvant as a premier
vaccine adjuvant through research collaborations and partnerships.
Current collaborations are focused on adjuvanted vaccines for
COVID-19, pertussis, universal influenza and plague. For more
information, visit www.dynavax.com and follow the company on
LinkedIn.
Contacts:
Nicole Arndt,
Investor Relations
narndt@dynavax.com
510-665-7264
Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/scott-myers-appointed-to-dynavax-board-of-directors-and-elected-board-chairman-301406163.html
SOURCE Dynavax Technologies